Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

February 6, 2019

Study Completion Date

February 6, 2019

Conditions
Alzheimer Disease
Interventions
DRUG

NPT088

IgG1 Fc-GAIM fusion protein, a recombinant fusion protein

DRUG

Placebo

Placebo

Trial Locations (23)

11229

Integrative Clinical Trials, Inc., Brooklyn

12208

Neurological Associates of Albany, Albany

18104

Lehigh Center for Clinical Research, Allentown

19090

Abington Neurological Associates, Ltd, Willow Grove

28270

Alzheimer's Memory Center, Charlotte

30033

NeuroStudies LLC, Decatur

31909

Medical Research and Health Education Foundation, Columbus

32137

Progressive Medical Research, Port Orange

32162

Compass-The Villages, The Villages

32763

Medical Research Group of Central Florida, Orange City

32806

Compass Research, Orlando

33012

Indago Research and Health Center, Hialeah

33137

Miami Jewish Health Systems, Miami

33449

Alzheimer's Research and Treatment Center, Lake Worth

33462

JEM Research Institute, Atlantis

33609

Axiom Clinical Research, Tampa

38018

Neurology Clinic, PC, Cordova

90806

Collaborative Neuroscience Network, Long Beach

92626

ATP Clinical Research, Inc., Costa Mesa

92835

Neurology Center of North Orange County, Fullerton

93065

Southern California Research, Simi Valley

06824

Associated Neurologists of Southern Connecticut, Fairfield

08540

Princeton Medical Institute, Princeton

Sponsors
All Listed Sponsors
collaborator

Alzheimer's Association

OTHER

lead

Proclara Biosciences, Inc.

INDUSTRY